Pfizer CEO Not ‘Chasing Revenue’ in Deals as Patents Expire

Pfizer Inc. Chief Executive Officer Ian Read said he won’t seek large deals to replace falling revenue, as the world’s biggest drugmaker loses patent exclusivity to drugs responsible for 60 percent of yearly sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.